BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 23751372)

  • 1. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy.
    Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M
    Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer.
    May M; Burger M; Brookman-May S; Stief CG; Fritsche HM; Roigas J; Zacharias M; Bader M; Mandel P; Gilfrich C; Seitz M; Tilki D
    Clin Genitourin Cancer; 2014 Aug; 12(4):278-86. PubMed ID: 24331576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
    Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H
    Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.
    Moschini M; Sharma V; Dell'oglio P; Cucchiara V; Gandaglia G; Cantiello F; Zattoni F; Pellucchi F; Briganti A; Damiano R; Montorsi F; Salonia A; Colombo R
    BJU Int; 2016 Apr; 117(4):604-10. PubMed ID: 25851271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing and outcomes for radical cystectomy in nonmuscle invasive bladder cancer.
    Zehnder P; Thalmann GN
    Curr Opin Urol; 2013 Sep; 23(5):423-8. PubMed ID: 23880740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
    BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis.
    Chen J; Zhang H; Sun G; Zhang X; Zhao J; Liu J; Shen P; Shi M; Zeng H
    Int J Surg; 2018 Apr; 52():214-220. PubMed ID: 29496649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature.
    Soukup V; Babjuk M; Bellmunt J; Dalbagni G; Giannarini G; Hakenberg OW; Herr H; Lechevallier E; Ribal MJ
    Eur Urol; 2012 Aug; 62(2):290-302. PubMed ID: 22609313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
    Kayama E; Kikuchi E; Fukumoto K; Shirotake S; Miyazaki Y; Hakozaki K; Kaneko G; Yoshimine S; Tanaka N; Takahiro M; Kanai K; Oyama M; Nakajima Y; Hara S; Monma T; Oya M
    Clin Genitourin Cancer; 2018 Oct; 16(5):e969-e976. PubMed ID: 29778322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
    Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
    Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables.
    Altieri VM; Castellucci R; Palumbo P; Verratti V; Sut M; Olivieri R; Manco R; Ricciardulli S; Nicolai M; Criniti P; Tenaglia RL
    Urol Int; 2012; 89(1):61-6. PubMed ID: 22722366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
    Grossmann NC; Rajwa P; Quhal F; König F; Mostafaei H; Laukhtina E; Mori K; Katayama S; Motlagh RS; Fankhauser CD; Mattei A; Moschini M; Chlosta P; van Rhijn BWG; Teoh JYC; Compérat E; Babjuk M; Abufaraj M; Karakiewicz PI; Shariat SF; Pradere B
    Eur Urol Open Sci; 2022 May; 39():14-21. PubMed ID: 35528782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncological Outcome of Primary and Secondary Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Ge P; Wang L; Lu M; Mao L; Li W; Wen R; Lin J; Wang J; Chen J
    Sci Rep; 2018 May; 8(1):7543. PubMed ID: 29765120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients.
    Koga F; Numao N; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    Urol Oncol; 2013 Oct; 31(7):1270-5. PubMed ID: 22386622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.